Literature DB >> 28878841

Thyroid Association Ophthalmopathy in Hashimoto's Thyroiditis: a Case Report.

Deepak Jain1, Sudhir Mor2, Hari Krishan Aggarwal3, Pulkit Chhabra2, Promil Jain4.   

Abstract

Thyroid associated ophthalmopathy is a constellation of symptoms caused by an autoimmune process involving the orbital tissue. It is common in hyperthyroid patients due to Graves' disease and also reported in euthyroid and hypothyroid Graves' patients with positive thyroid receptor antibodies. But in Hashimoto's thyroiditis, thyroid associated ophthalmopathy is a rarely reported and poorly understood entity. Here we report thyroid associated ophthalmopathy in a patient with hypothyroidism and negative thyroid receptor antibodies who showed heterogeneously hypoechoic thyroid gland on ultrasonography, diffuse lymphocytic infiltrate on fine needle aspiration citology and reduced 99m Tc radioisotope uptake, supporting the diagnosis of Hashimoto's thyroiditis. The patient was treated with levothyroxine and artificial tear drops.

Entities:  

Year:  2017        PMID: 28878841      PMCID: PMC5574077     

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  11 in total

1.  Unilateral ophthalmopathy in a patient with Hashimoto's thyroiditis.

Authors:  Y Tomer
Journal:  Thyroid       Date:  2000-01       Impact factor: 6.568

2.  Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients.

Authors:  H Tamai; K Kasagi; Y Takaichi; J Takamatsu; G Komaki; S Matsubayashi; J Konishi; K Kuma; L F Kumagai; S Nagataki
Journal:  J Clin Endocrinol Metab       Date:  1989-07       Impact factor: 5.958

3.  Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.

Authors:  Marenza Leo; Francesca Menconi; Roberto Rocchi; Francesco Latrofa; Eleonora Sisti; Maria Antonietta Profilo; Barbara Mazzi; Eleonora Albano; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Thyroid       Date:  2015-02-11       Impact factor: 6.568

Review 4.  IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity.

Authors:  Wah Cheuk; John K C Chan
Journal:  Adv Anat Pathol       Date:  2010-09       Impact factor: 3.875

5.  Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.

Authors:  R W Valyasevi; D Z Erickson; D A Harteneck; C M Dutton; A E Heufelder; S C Jyonouchi; R S Bahn
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

6.  Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues.

Authors:  R Paschke; A Metcalfe; L Alcalde; G Vassart; A Weetman; M Ludgate
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

7.  Thyrotropin receptor antibodies in hypothyroid Graves' disease.

Authors:  K Kasagi; A Hidaka; H Nakamura; R Takeuchi; T Misaki; Y Iida; J Konishi
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

8.  Thyroid-associated orbitopathy in patients with Hashimoto's thyroiditis: a case report.

Authors:  Wiesław Grzesiuk; Dorota Szydlarska; Aneta Pragacz; Ewa Bar-Andziak
Journal:  Pol Arch Med Wewn       Date:  2008-05

9.  Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy.

Authors:  Katharina A Ponto; Harald Binder; Tanja Diana; Nina Matheis; Anna F Otto; Susanne Pitz; Norbert Pfeiffer; George J Kahaly
Journal:  Thyroid       Date:  2015-06-04       Impact factor: 6.568

Review 10.  Graves' ophthalmopathy: state of the art and perspectives.

Authors:  L Bartalena; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

View more
  1 in total

1.  Teprotumumab: a disease modifying treatment for graves' orbitopathy.

Authors:  Michelle Ting; Daniel G Ezra
Journal:  Thyroid Res       Date:  2020-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.